Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 5/20 | 0.70 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.70 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.70 |
| ▸ | PRKCA | P17252 | 1/20 | 0.67 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.67 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.67 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.67 |
| ▸ | P2RY10 | O00398 | 6/20 | 0.62 |
| ▸ | GPR174 | Q9BXC1 | 3/20 | 0.62 |
| ▸ | GPR34 | Q9UPC5 | 3/20 | 0.62 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dexfosfoserine SCHEMBL28487121 | 1.00 | ENPP2 (0.70) | ENPP2LPAR3LPAR1SMN1; SMN2PRKCA | |
| Dexfosfoserine SCHEMBL28465640 | 1.00 | ENPP2 (0.70) | ENPP2LPAR3LPAR1SMN1; SMN2PRKCA | |
| Dexfosfoserine SCHEMBL28837002 | 1.00 | ENPP2 (0.70) | ENPP2LPAR3LPAR1SMN1; SMN2PRKCA | |
| Dexfosfoserine SCHEMBL28767573 | 1.00 | ENPP2 (0.70) | ENPP2LPAR3LPAR1SMN1; SMN2PRKCA | |
| Monoctanoin Component C SCHEMBL29239955 | 1.00 | ENPP2 (0.70) | ENPP2LPAR3LPAR1SMN1; SMN2PRKCA | |
| Dexfosfoserine SCHEMBL23881437 | 0.94 | S1PR1 (0.71) | ENPP2PRKCAPRKCEPRKCQPRKCD | |
| Diolein SCHEMBL20336979 | 0.94 | S1PR1 (0.71) | ENPP2PRKCAPRKCEPRKCQPRKCD | |
| Serine SCHEMBL29285065 | 0.91 | ENPP2 (0.78) | ENPP2LPAR3LPAR1SMN1; SMN2PRKCA | |
| Serine SCHEMBL29285064 | 0.91 | ENPP2 (0.78) | ENPP2LPAR3LPAR1SMN1; SMN2PRKCA | |
| Serine SCHEMBL28475931 | 0.91 | ENPP2 (0.78) | ENPP2LPAR3LPAR1SMN1; SMN2PRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11504328-B2 | Method for preparing liposome comprising ultrasound reactive microbubble for drug delivery and liposome using same | BIOINFRA LIFE SCIENCE INC. (KR) | 2022-11-22 | — | — | US | claimed |
| WO-2019182353-A1 | METHOD FOR PREPARING LIPOSOME COMPRISING ULTRASOUND REACTIVE MICROBUBBLE FOR DRUG DELIVERY AND LIPOSOME USING SAME | (주) 바이오인프라생명과학 | 2019-09-26 | — | — | WO | claimed |
| CN-115315252-A | Antiviral composition for preventing or treating infection or respiratory disease after exposure | 盈擘医药股份有限公司 | 2022-11-08 | — | — | CN | disclosed |
| CN-114845728-A | Microparticle-based enzyme system for selective removal of target molecules | 合成生命股份有限公司 | 2022-08-02 | — | — | CN | disclosed |
| CN-113271937-A | Method and apparatus for treating pruritus associated with chronic kidney disease | 艾维奥尔股份有限公司 | 2021-08-17 | — | — | CN | disclosed |
| CN-112512508-A | Sustained-release pharmaceutical composition containing therapeutic agent for treating dementia and use thereof | 台湾微脂体股份有限公司 | 2021-03-16 | — | — | CN | disclosed |
| CN-112272554-A | Transmucosal film compositions and methods of making and using same | 艾维奥尔股份有限公司 | 2021-01-26 | — | — | CN | disclosed |
| CN-112004527-A | Inhalable liposome sustained-release composition for treating pulmonary diseases | 美商TLC生物医药公司 | 2020-11-27 | — | — | CN | disclosed |
| CN-111971028-A | Enhancing training immunity with therapeutic nanobiotic compositions | 西奈山伊坎医学院 | 2020-11-20 | — | — | CN | disclosed |
| WO-2019182353-A1 | METHOD FOR PREPARING LIPOSOME COMPRISING ULTRASOUND REACTIVE MICROBUBBLE FOR DRUG DELIVERY AND LIPOSOME USING SAME | (주) 바이오인프라생명과학 | 2019-09-26 | — | — | WO | disclosed |